Dublin, Ireland – April 12, 2024 — Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) and Medtronic plc (NYSE: MDT), a global leader in healthcare technology, jointly announced significant advancements in artificial intelligence (AI) for gastrointestinal care at the Genius Summit 2024. Central to this innovation is the introduction of ColonPRO™, the next-generation software for the GI Genius™ intelligent endoscopy system developed by Cosmo IMD.
Enhanced Detection Capabilities with ColonPRO™
GI Genius™ was the first commercially available AI-powered polyp detection system in endoscopy. Its impact has been validated through more than 30 academic and real-world studies involving over 23,000 patients. The new ColonPRO™ software features an advanced algorithm trained on a dataset twice as large as the previous version, resulting in a 9% reduction in false positives and significantly improved detection of colorectal polyps.
Workflow Automation and EHR Integration
The system now includes a new “procedural highlights” feature to streamline documentation, automate workflow, and prepare for integration with electronic health records (EHRs). This update positions GI Genius™ to not only enhance clinical performance but also reduce administrative burden for physicians.
Strategic Collaboration with ModMed
Medtronic also announced a new partnership with Modernizing Medicine® (ModMed) to integrate GI Genius™ insights into ModMed’s gGastro® EHR software. This collaboration aims to boost efficiency and bring real-time AI-assisted decision-making to the point of care.
Executive Commentary
“Through our collaboration with ModMed, we can streamline workflows and leverage augmented decision-making,” said Raj Thomas, President of the Endoscopy business at Medtronic.
“ColonPRO™ will accelerate new features and unlock the full potential of our AI Access™ platform,” said Nhan Ngo Dinh, President at Cosmo Intelligent Medical Devices.
Joint Vision for the Future of GI Care
Together, Cosmo and Medtronic are setting a new standard in colorectal cancer care by integrating AI capabilities with practical clinical workflows. Their continued innovation reflects a shared commitment to supporting physicians and improving outcomes for patients around the world.
About Cosmo Pharmaceuticals
Cosmo is a specialty pharma company focused on gastrointestinal and dermatological therapies. It develops and manufactures globally distributed products including Lialda®, Uceris®, Aemcolo®, and Winlevi®. Cosmo is the developer of GI Genius™, an AI-powered endoscopy system, distributed by Medtronic. The company maintains a strong development pipeline and strategic focus on intelligent medical devices.
For more information, visit www.cosmopharma.com.
By
